以硼替佐米为基础的化疗在多发性骨髓瘤患者中的应用效果

打开文本图片集

[Abstract]Objective： To investigate the application efect of Bortezomib-based chemotherapy in patients with multiple myeloma.Method： A total of6O multiple myeloma patientsadmited tothe Department of Hematology， Yichun People's Hospital from February 2O2O to February 2O22 were selected as the study subjects.They were divided into two groups according to the random number table method. The control group （ n =30）was treated with the Rd regimen，and the observation group （n=3O） was treated withthe RVD regimen.The immune-related cytokines，basic Tcellsubsets，functional Tcellsubsets and curativeefects were compared between the two groups. Result：After 4courses of treatment，the levelsof helperTcell17（Th17）inboth groups decreased，thelevelsof CD4+/CD8+and regulatory Tcells （Treg） increased，and those in the observation group were superior to the control group （ P <0.05）.Compared with the control group，the levels of transforming growth factor- β1 （TGF- |3 1 ，IL-17 and IL-6 in the observation group after 4 courses of treatment were lower （ P <0.05）. After 4 courses of treatment， the total effective rate of treatment in the observation groupwas higher than that in the control group （ P <0.05）.Conclusion： For patients with multiple myeloma，chemotherapy regimen based on Bortezomib can regulate Tcel subsets，improve immune-related cytokines，and enhance curative effect.

[Keywords] Multiple myelomaBortezomibTcell subsets

First-author'saddress：DepartmentofHematology，YichunPeople's Hospital，Yichun3360o，China doi：10.3969/j.issn.1674-4985.2025.32.001

多发性骨髓瘤（multiplemyeloma，MM）是一种比较常见的血液恶性肿瘤，在全身恶性肿瘤中占 ，其是以骨髓浆细胞增生异常为主要特征的一种浆细胞肿瘤[2]。（剩余6604字）